^
BIOMARKER:

DNMT3A mutation

i
Other names: DNMT3A, DNA Methyltransferase 3 Alpha, DNA (Cytosine-5-)-Methyltransferase 3 Alpha, DNA (Cytosine-5)-Methyltransferase 3A, DNA MTase HsaIIIA, DNA Cytosine Methyltransferase 3A2, DNA Methyltransferase HsaIIIA, DNMT3A2, Dnmt3a
Entrez ID:
Related biomarkers:
DNMT3A mutation
MDS
RVU120
Sensitive: C4 – Case Studies
EHA 2022 - 4 days - (New C4)
DNMT3A mutation
AML
azacitidine
Resistant: B - Late Trials
DNMT3A mutation
AML
venetoclax + midostaurin
Resistant: C3 – Early Trials
DNMT3A mutation
MDS
pembrolizumab
Sensitive: C3 – Early Trials
DNMT3A mutation
AML
cytarabine
Resistant: C3 – Early Trials
DNMT3A mutation
AML
venetoclax
Sensitive: C3 – Early Trials
DNMT3A mutation
AML
venetoclax + gilteritinib
Resistant: C3 – Early Trials
DNMT3A mutation
AML
venetoclax + sorafenib
Resistant: C3 – Early Trials
DNMT3A mutation
MDS
azacitidine
Resistant: C3 – Early Trials
DNMT3A mutation
MDS
decitabine
Resistant: C3 – Early Trials
DNMT3A mutation
AML
quizartinib
Sensitive: C3 – Early Trials
DNMT3A mutation
CML
YD312
Resistant: C3 – Early Trials
DNMT3A mutation
AML
decitabine / cedazuridine
Sensitive: C3 – Early Trials
DNMT3A mutation
CRC
sintilimab + fruquintinib
Resistant: C3 – Early Trials
DNMT3A mutation
T Cell Non-Hodgkin Lymphoma
lenalidomide
Resistant: C3 – Early Trials
DNMT3A mutation
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
DNMT3A mutation
AML
DCAG
Sensitive: C3 – Early Trials
DNMT3A mutation
AML
RVU120
Sensitive: C3 – Early Trials
DNMT3A mutation
Peripheral T-cell Lymphoma
CHOP
Resistant: C3 – Early Trials
DNMT3A mutation
AML
EPZ-5676
Sensitive: D – Preclinical
DNMT3A mutation
AML
ABBV-744
Sensitive: D – Preclinical